Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flora Peyvandi

Showing results (481-490 of 500) with videos related to

Pageof 50
Sort By:
Human Gene Therapy|February 14, 2022
Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia ARobert Klamroth, Gregory Hayes, Tatiana Andreeva, et al.
Journal of Thrombosis and Haemostasis : JTH|September 7, 2023
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1Brian O'Mahony, Amy L Dunn, Andrew D Leavitt, et al.
American Journal of Hematology|October 10, 2022
The role of hypoxia and inflammation in the regulation of iron metabolism and erythropoiesis in COVID-19: The IRONCOVID studyDiletta Maira, Lorena Duca, Fabiana Busti, et al.
The New England Journal of Medicine|February 22, 2023
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia AJohnny Mahlangu, Radoslaw Kaczmarek, Annette von Drygalski, et al.
Journal of Thrombosis and Haemostasis : JTH|February 15, 2023
von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPSMaria Teresa Pagliari, Ulrich Budde, Luciano Baronciani, et al.
Blood Advances|August 5, 2021
Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPSLuciano Baronciani, Ian Peake, Reinhard Schneppenheim, et al.
Journal of Clinical Medicine|October 24, 2020
The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in CaucasiansIlaria Mancini, Elisa Giacomini, Silvia Pontiggia, et al.
Journal of Thrombosis and Haemostasis : JTH|January 29, 2022
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS studyMaria Teresa Pagliari, Frits R Rosendaal, Minoo Ahmadinejad, et al.
Journal of Thrombosis and Haemostasis : JTH|May 8, 2020
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional studyAlberto Tosetto, Zahra Badiee, Mohammad-Reza Baghaipour, et al.
Blood Advances|January 29, 2024
Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders DatabaseSamin Mohsenian, Roberta Palla, Marzia Menegatti, et al.
Pageof 50

Showing results (481-490 of 500) with videos related to

Sort By:
Pageof 50
Human Gene Therapy|February 14, 2022
Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia ARobert Klamroth, Gregory Hayes, Tatiana Andreeva, et al.
Journal of Thrombosis and Haemostasis : JTH|September 7, 2023
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1Brian O'Mahony, Amy L Dunn, Andrew D Leavitt, et al.
American Journal of Hematology|October 10, 2022
The role of hypoxia and inflammation in the regulation of iron metabolism and erythropoiesis in COVID-19: The IRONCOVID studyDiletta Maira, Lorena Duca, Fabiana Busti, et al.
The New England Journal of Medicine|February 22, 2023
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia AJohnny Mahlangu, Radoslaw Kaczmarek, Annette von Drygalski, et al.
Journal of Thrombosis and Haemostasis : JTH|February 15, 2023
von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPSMaria Teresa Pagliari, Ulrich Budde, Luciano Baronciani, et al.
Blood Advances|August 5, 2021
Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPSLuciano Baronciani, Ian Peake, Reinhard Schneppenheim, et al.
Journal of Clinical Medicine|October 24, 2020
The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in CaucasiansIlaria Mancini, Elisa Giacomini, Silvia Pontiggia, et al.
Journal of Thrombosis and Haemostasis : JTH|January 29, 2022
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS studyMaria Teresa Pagliari, Frits R Rosendaal, Minoo Ahmadinejad, et al.
Journal of Thrombosis and Haemostasis : JTH|May 8, 2020
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional studyAlberto Tosetto, Zahra Badiee, Mohammad-Reza Baghaipour, et al.
Blood Advances|January 29, 2024
Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders DatabaseSamin Mohsenian, Roberta Palla, Marzia Menegatti, et al.
Pageof 50